
David McCall MD
Pediatric Hematologic Oncology
Assistant Professor
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. McCall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Medical College of Georgia at Augusta UniversityClass of 2014
Certifications & Licensure
- TX State Medical License 2017 - 2027
- WA State Medical License 2023 - 2026
- AL State Medical License 2016 - 2025
- AZ State Medical License 2023 - 2025
- GA State Medical License 2023 - 2025
- LA State Medical License 2023 - 2025
- MS State Medical License 2023 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
- Join now to see all
Clinical Trials
- A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2022 Oct 05
Roles: Contact, Principal Investigator
- Impact Of Muscle Vibration On Gait Control Start of enrollment: 2021 Oct 04
Roles: Principal Investigator, Contact
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia Start of enrollment: 2023 Jul 14
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.Olayinka Okeleji, David McCall, Amber Gibson, Miriam B Garcia, Cesar Nunez
Blood Advances. 2025-04-22 - The Need for Concurrent Chemoimmunotherapy in Pediatric B-Cell Lymphoblastic Leukemia.David McCall, Seth E Karol, Nicholas J Short
Acta Haematologica. 2025-03-07 - Treatment of a Pediatric Patient with Core Binding Factor Acute Myeloid Leukemia Post-Cytotoxic Therapy With Cytarabine, Daunorubicin, and Gemtuzumab Followed by Stem ...Irtiza N Sheikh, Destiny Uwaezuoke, Olayinka Okeleji, Andres Quesada, Cynthia E Herzog
Pediatric Blood & Cancer. 2025-03-01
Press Mentions
- ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory DisorderDecember 9th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: